AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06221683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100mg/m2/q12h for weighing >10kg, 3.3mg/kg/q12h for weighing ≤10kg, d1-7, ivgtt, q12h, more than 30 minutes in SDC group; 10mg/m2/q12h for weighing >10kg, 0.33mg/kg/q12h for weighing ≤10kg, d1-10, s.c.,q12h (the first dose at 8 am) in the LDC group;
Study NCT06221683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/m2/d for weighing >10kg, 3.3mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 4 hours
Study NCT05761431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2008 injection
Description: Subcutaneous administration on Day 1.
Study NCT05761431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate Microspheres for Injection injection
Description: Intramuscular administration on Day 1.
Study NCT05761431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin ® injection
Description: Subcutaneous administration on Day 1.
Study NCT06221683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 100mg/m2/d for weighing >10kg, 3.33mg/kg/d for weighing ≤10kg, d12-25, po, qd
Study NCT06221683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome
Description: 5mg/m2/d for weighing >10kg, 0.17mg/kg/d for weighing ≤ 10kg, d1, 3, 5, ivgtt, qod, more than 2 hours at 10 am.
Study NCT05761431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to SYHX2008 injection
Description: Subcutaneous administration on Day 1.
Study NCT06221683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Granulocyte Colony-Stimulating Factor
Description: 5ug/kg/d, d1-10, s.c., qd, at 1pm
Study NCT06221683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin Hydrochloride
Description: 3mg/m2/day for weighing >10kg, 0.1mg/kg/day for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 6 hours.
Study NCT06221683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 100mg/m2/day for weighing >10kg, 3.3mg/kg/day for weighing ≤10kg, from identification, po, qd
Study NCT06221683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: 20mg/m2/day for weighing >10kg, 0.7mg/kg/day for weighing ≤ 10kg, from identification, po, qd
Study NCT06221683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: 50mg/m2/day for weighing bodyweight >10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd
Study NCT05235737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol
Study NCT05235737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol
Study NCT04791865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure intervention
Description: Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).
Study NCT04791865 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
Study NCT05591352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chenopodium formosanum extracts sachet
Description: consume 1 sachet per day
Study NCT05591352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: consume 1 sachet per day
Study NCT06496893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IP 1200 mg per soft gel capsule
Description: Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
Study NCT06496893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo 1200 mg per soft gel capsule
Description: Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
Study NCT04393883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
Description: (A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
Study NCT04393883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
Description: (B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
Study NCT04326491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Biopsy
Description: Analysis of breath samples to identify volatile molecules specific to HCC
Study NCT04827004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib capsules given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Study NCT05416359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3915 tablets
Description: TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.
Study NCT06084273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath Exercises
Description: The Bobath approach aims to enhance postural and neuromotor control goal-directedly, leading to functional improvement. Our study selected the Bobath 30 exercises from the fundamental exercises to create a program specific to the goal and targeting functionality.~The ten Bobath exercises performed by all participants in the study are as follows: Bridging Exercise, Latissimus Stretch Exercise, Autoinhibition Exercise, Dorsiflexion Training, Sitting Balance Training, Upper Extremity Weight Shifting Exercise, Lower Extremity Weight Shifting Exercise, Oblique Abdominal Strengthening Exercise, Knee Control Training, and Walking Training.
Study NCT06084273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises,Breathing Exercises, Bobath Exercises
Description: The puckered lip breathing exercise aims to prevent the closure of the small airways by creating pressure during expiration. During the exercise, the individual is asked to follow these steps:~1. Breathe calmly and slowly through the nose.~2. Pucker the lips as if whistling or inflating a balloon.~3. Exhale the breath with puckered lips. Relaxation exercises Progressive Muscle Relaxation Technique: Progressive muscle relaxation is one of the easiest methods to learn and apply, developed by Jacobson. It involves voluntarily tensing and relaxing large muscle groups regularly and sequentially. The participant was encouraged to wear comfortable clothing, breathe deeply, and exhale. The technique can be performed in a sitting or lying position. Music can be played to contribute to the participant's relaxation.
Study NCT05021328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg, ivgtt, d1, q3w.
Study NCT05021328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12 mg/d, d1-14, q3w.
Study NCT05021328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBRT 7Gy✖️5 QD
Description: SBRT 7Gy✖️5 QD
Study NCT04953208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Treatment will be applied daily 5 days/week for a period of 6 weeks, which equals a tDCS stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
Study NCT04953208 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
Study NCT04953208 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive and emotional control video game
Description: a video game targeting cognitive and emotional control. total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
Study NCT04953208 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham video game
Description: a video game which does not target cognitive control, played for total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
Study NCT05538169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser diode (Pioon Laser)
Description: Settings: the spot tip area of this tool is 0.088 cm2, semi-conductor diode, with a wavelength of 980 nm (near infrared), 200 mW output power, 1.97W/cm2 of power density, 3 J energy per point and application time 15 seconds per point\].~* PBM will apply punctually, in continuous emissions.~* Extra-oral points: six points on each parotid gland, three points on each submandibular gland.~* Intra-oral points: two points on each sublingual gland.~* A total of 22 points will be applied in each session.
Study NCT06497361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRG-2311
Description: PRG-2311 (CD19/BCMA-targeting CAR-T Cells)
Study NCT05465707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 2 mg/kg
Description: Once 1 week, intravenous infusion.
Study NCT05465707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 4 mg/kg
Description: Once 1 week, intravenous infusion.
Study NCT05465707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 8 mg/kg
Description: Once 1 week, intravenous infusion.
Study NCT05465707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 16 mg/kg
Description: Once 1 week, intravenous infusion.
Study NCT05465707 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once 1 week, intravenous infusion.
Study NCT05335837 — intervention group
Intervention type: PROCEDURE
Intervention: Regional Anesthesia and Sedation
Description: Preoperative ilioinguinal/iliohypogastric nerve block and moderate to deep intraoperative sedation.
Study NCT06381206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Selective Alpha Blocker drug
Study NCT04166474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dosed at 50 mg bd on 3 separate occasions with low, medium and high doses of rifampicin. Dosed at 50 mg od without rifampicin.
Study NCT06478472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib in combination with rituximab
Description: Induction Phase:~Orelabrutinib + rituximab for a total of 6 cycles of 28 days each Obrutinib (O) 150mg oral d1-28 Rituximab (R) 375mg/m2 IV d0~Maintenance phase:~Orelabrutinib 150mg po qd 24 cycles of 28 days each
Study NCT05481892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Home blood pressure (BP) monitoring
Description: Patients receiving intervention will receive cellular home blood pressure (BP) monitoring devices. Some patients will also receive pharmacist support for treatment intervention.
Study NCT05481892 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellular Home blood pressure (BP) monitoring
Description: Patients receiving intervention will receive cellular home blood pressure (BP) monitoring devices. Some patients will also receive pharmacist support for treatment intervention.
Study NCT05035719 — intervention group
Intervention type: DEVICE
Intervention: non-invasive cardiac output monitor
Description: Equivalence of Caretaker cardiac output reading to reference standard
Study NCT06462209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ladder training
Description: Players practiced Ladder training for 60 minutes thrice a week for 8 weeks. There are 3 different types of drills. The first types of drills are steady state drills. These drills focus on quickness Endurance and utilize a constant rhythm throughout the ladder. The second types of drills are burst drills. These drills focus on the ability to turn on rapid burst of foot movement.~The third types of drills are elastic response drills. These drills focus on improving the reactive speed components of the lower leg. A standard agility ladder is 15 feet long and 20 inches wide Step.
Study NCT06462209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plyometric training
Description: In plyometric training players practiced for 60 minutes thrice a week for 8 weeks. warm up for 15 minutes , plyometric training for 30 minutes and cool down for 15 minutes
Study NCT06419673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Study NCT06419673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT06419673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT06419673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT06419673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT06419673 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy and External Beam Radiotherapy
Description: Brachytherapy and External Beam Radiotherapy
Study NCT06419673 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy and External Beam Radiotherapy
Description: Brachytherapy and External Beam Radiotherapy
Study NCT05280873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone, methylprednisolone
Description: Methylprednisolone 2 mg / kg / d+ pirfenidone (starting from 200mg tid, increasing to 600mg tid within one week and maintaining) . Methylprednisolone was reduced according to the researcher's evaluation of the patient's condition and the specific course of treatment was determined.
Study NCT05280873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 2 mg / kg / d . Methylprednisolone was gradually reduced after the improvement of symptoms and imaging. The treatment course was 6-8 weeks
Study NCT06542744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with the Emagina device at home until birth
Description: The subjects will use the device at home according to a series of 3 exercises, 2 sessions per week, followed by a series of 4 exercises, 3 sessions per week starting from D75.
Study NCT05231811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Pregnant women by the researcher; Foot massage consisting of classical massage techniques will be applied in a room in the clinic reserved for this application. During the massage; A pillow will be placed under the patient's leg and a disposable cover will be placed on the pillow. During the massage, pregnant women will be massaged with baby oil or vaseline cream. The soles of the pregnant women will be rubbed by the practitioner's fingers. The practitioner will make circular movements by applying pressure to the sole of the pregnant woman's feet with her thumb, and will apply pressure to the foot with up and down movements, using the joint protrusions on the upper surface of the hand that she has made into a fist. The heel and ankle will be squeezed between the thumb and forefinger of the researcher and kneaded and the massage will be terminated. During the application, the researcher who performs the massage will pay attention to the precautions applied in the hospital.
Study NCT05090436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Exercise
Description: two month (three session per week)
Study NCT05090436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (physiotherapy techniques)
Description: two month (three session per week)
Study NCT05691127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count (CBC), C reactive protein (CRP(., Chest x ray, ABG, Electrolytes, Random blood sugar, Creatinine
Description: I will use these investigations in my study
Study NCT06485102 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid Surgery in patients with symptomatic or asymptomatic stenosis
Description: Carotid Surgery in patients with symptomatic or asymptomatic stenosis
Study NCT06542744 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: The subjects will follow usual care instructions. Subjects are not trained in the use of Emagina.
Study NCT06070168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Mothers in labor after normal birth at the postpartum clinic At least 6 hours later and for cesarean births, the researcher will visit the patient after 12 hours.~Mothers will be interviewed according to the inclusion criteria and exclusion criteria, and will be informed about the study.~will be given and their consent will be taken, the mother information form and the Edinburgh Postpartum Depression Scale (EPDS) form will be filled in, a pre-test will be done and the communication will be completed.~will get their numbers. The researcher will contact the experimental group by phone. He will introduce himself and 6 weeks (during postpartum) It will provide the mother with the consultancy service she needs about herself and the newborn 24 hours a day. After 6 weeks, the training will end and the third researcher will make post-tests of the depression scale to both groups without knowing the experimental and control groups.
Study NCT06108674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care via telepharmacy and usual care
Description: Pharmacotherapeutic monitoring via telephone consultation
Study NCT06108674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical care in-person and usual care
Description: Face-to-face pharmacotherapeutic monitoring
Study NCT05891873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CAM-ICU
Description: Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
Study NCT05891873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ICDSC
Description: Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
Study NCT05891873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 4AT
Description: Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
Study NCT05891873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: p(s)CAM-ICU
Description: Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
Study NCT05891873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CAPD
Description: Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
Study NCT05891873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MASTcz (The Mississippi Aphasia Screening Test)
Description: People with aphasia will be examined by a skilled speech therapist.
Study NCT05891873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EEG
Description: Patients with positive delirium will undergo EEG examination. 10-min native EEG.
Study NCT05885529 — intervention group
Intervention type: OTHER
Intervention: UCH-L1 GFAP
Description: measurment of UCH-L1 GFAP within 12 hours in adult patients after a mild traumatic brain injury
Study NCT05266976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 Weeks of Supervised Resistance Exercise Training
Description: Participants will be randomized to complete 10 weeks of either resistance (weight lifting, hopping) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
Study NCT05266976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 Weeks of Supervised Endurance Exercise Training
Description: Participants will be randomized to complete 10 weeks of endurance (stationary cycling) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
Study NCT05539599 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive evaluation
Description: Non-ultrasound parameters: Central venous pressure, hand-grip strength evaluation, P0.1, Maximal inspiratory pressure, Blood gas analysis ultrasound parameters: Diaphragmatic displacement, thickening fraction, TFmax, E/e', Triscuspidal annular Plane Systolic Excursion, Lung score
Study NCT03912350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balovaptan
Description: Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.
Study NCT03912350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.
Study NCT05567601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOXIL/CAELYX
Description: 40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein